Christian Kellner
0000-0002-2562-6902
68 papers found
Refreshing results…
Fc Engineering of Antibodies and Antibody Derivatives by Primary Sequence Alteration and Their Functional Characterization
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Epidermal growth factor receptor (EGFR) expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
Identification and activity of the novel antibody MSH-TP15 by it cell-based phage display screening approach
Depletion of leukemic AML stem cells from autografts by CD96 antibody TH111
Recombinant immunoligands triggering activating NK cell receptors enhance antibody-dependent cell-mediated cytotoxicity synergistically
The novel ICAM-1/CD54 antibody MSH-TP15, identified by a cell-based phage display screening approach, has potent anti-myeloma activity in vitro and in vivo
Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
Antibody-Dependent Cellular Cytotoxicity in Patients on Chronic Hemodialysis
Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies
Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity
Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages*
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression
Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
Missing publications? Search for publications with a matching author name.